{
  "timestamp": "20250531_120644",
  "pipeline_tested": "BasicRAG",
  "num_queries_tested": 10,
  "successful_queries": 10,
  "results_per_query": [
    {
      "query": "What are the effects of metformin on type 2 diabetes?",
      "answer": "Metformin is often the first-line medication prescribed for type 2 diabetes. It helps lower glucose production in the liver and improves insulin sensitivity. This information is based on Document 1 (Diabetes Treatment Review) which highlights common treatments for type 2 diabetes, including the use of metformin. The document suggests that metformin plays a role in lowering glucose levels and improving insulin sensitivity in individuals with type 2 diabetes.",
      "contexts": [
        "Diabetes Treatment Review\n\nCommon treatments for type 2 diabetes include lifestyle changes such as diet and exercise, oral medications like metformin, and in some cases, insulin therapy. Metformin is ...",
        "",
        "The raising prevalence of type-2 diabetes mellitus and obesity has been recognized as a major problem for public health, affecting both developed and developing countries. Impaired fasting plasma gluc...",
        "Nocturnal hypoglycemia frequently occurs in patients with type 1 diabetes mellitus (T1DM). It can be fatal and is believed to promote the development of the hypoglycemia-unawareness syndrome. Whether ...",
        "Glycemic and Insulin Status in Periodontitis Patients using the Homeostasis Model Assessment (HOMA): A Pilot Study\n\nThis study aimed to compare insulin status and dysglycemia (prediabetes/diabetes) of..."
      ],
      "ground_truth": "Metformin helps treat type 2 diabetes by reducing glucose production in the liver and increasing insulin sensitivity in peripheral tissues.",
      "pipeline_name": "BasicRAG",
      "execution_time": 3.269468069076538,
      "num_docs": 5
    },
    {
      "query": "How does SGLT2 inhibition affect kidney function?",
      "answer": "Based on the information provided in the context, there is no direct mention of SGLT2 inhibition and its effect on kidney function. Document 1 discusses the influence of insulin and incretin-based therapies on renal tubular transport, Document 2 focuses on urinary Transforming Growth Factor-beta 1 as a marker of response to immunosuppressive treatment in crescentic nephritis, and Document 3 discusses the interplay between complement, inflammation, and bioincompatibility in hemodialysis.\n\nTherefore, based on the available information, it is not possible to provide a comprehensive answer to how SGLT2 inhibition affects kidney function. Additional research or information specifically addressing SGLT2 inhibition and its impact on kidney function would be needed to answer this question accurately.",
      "contexts": [
        "The influence of insulin and incretin-based therapies on renal tubular transport\n\nThe tubular function of the kidney is very complex and is finely regulated by many factors. These include a variety of...",
        "Crescentic nephritis is characterized by formation of cellular crescents that soon become fibrotic and result in irreversible damage, unless an effective immunosuppressive therapy is rapidly commenced...",
        "The Janus-faced nature of complement in hemodialysis: interplay between complement, inflammation, and bioincompatibility unveiling a self-amplifying loop contributing to organ damage\n\nIn hemodialysis ...",
        "Editorial: Optimizing outcomes for children with immune-mediated chronic kidney disease\n\n\n\nAuthors: Thomas Renson, Evelien Snauwaert, Lorraine Hamiwka, Susa Benseler, Lovro Lamot\n\nKeywords: immune-med...",
        "Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis\n\nIgA nephropathy (IgAN) is a common primary glomerular disease. The ..."
      ],
      "ground_truth": "SGLT2 inhibitors protect kidney function by reducing hyperfiltration, decreasing albuminuria, and providing nephroprotection through mechanisms independent of glycemic control.",
      "pipeline_name": "BasicRAG",
      "execution_time": 2.488769769668579,
      "num_docs": 5
    },
    {
      "query": "What is the mechanism of action of GLP-1 receptor agonists?",
      "answer": "The mechanism of action of GLP-1 receptor agonists involves activating the glucagon-like peptide-1 (GLP-1) receptor. These agonists are incretin-based therapies used in the management of type 2 diabetes and obesity. They have beneficial effects beyond improved glycemic control. However, the context does not provide specific details on the exact mechanism of action of GLP-1 receptor agonists. Additional information on how these agonists interact with the GLP-1 receptor to exert their effects on gastric, biliary, and intestinal motility would be needed to fully answer this question.",
      "contexts": [
        "Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility\n\nGlucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1- and glucose-dependent...",
        "The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a human embryonic kidney cell system stably expressing only the mouse \u03ba-opioid recept...",
        "The Na A  Here we have tested the role of spinal NKCC1 cotransporters and TRPV1 receptors in referred allodynia in a model of visceral hyperalgesia in mice. Intrathecal (IT) injection of the NKCC1 inh...",
        "Genetic perturbations of \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors (AMPARs) are widely used to dissect molecular mechanisms of sensory coding, learning, and memory. In this study, we ...",
        ""
      ],
      "ground_truth": "GLP-1 receptor agonists work by stimulating insulin secretion, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety, ultimately improving glycemic control and often leading to weight loss.",
      "pipeline_name": "BasicRAG",
      "execution_time": 2.7796220779418945,
      "num_docs": 5
    },
    {
      "query": "What are the cardiovascular benefits of SGLT2 inhibitors?",
      "answer": "The context provided does not directly mention the cardiovascular benefits of SGLT2 inhibitors. The documents focus on diabetes treatment, microsomal triglyceride transfer protein inhibitors, and the effects of Candesartan on insulin sensitivity in non-diabetic, non-hypertensive subjects with dysglycemia and abdominal obesity. \n\nSGLT2 inhibitors, also known as sodium-glucose cotransporter 2 inhibitors, are a class of medications commonly used to treat type 2 diabetes. They work by blocking the reabsorption of glucose in the kidneys, leading to the excretion of excess glucose in the urine. In addition to their glucose-lowering effects, SGLT2 inhibitors have been shown to have cardiovascular benefits.\n\nStudies have demonstrated that SGLT2 inhibitors can reduce the risk of major cardiovascular events, such as heart attacks and strokes, in patients with type 2 diabetes. They have also been shown to lower blood pressure, reduce the risk of heart failure, and improve overall cardiovascular outcomes. Additionally, SGLT2 inhibitors have been associated with a reduction in cardiovascular mortality in patients with diabetes and cardiovascular disease.\n\nIn conclusion, SGLT2 inhibitors have shown significant cardiovascular benefits in addition to their primary role in managing blood sugar levels in patients with type 2 diabetes.",
      "contexts": [
        "Diabetes Treatment Review\n\nCommon treatments for type 2 diabetes include lifestyle changes such as diet and exercise, oral medications like metformin, and in some cases, insulin therapy. Metformin is ...",
        "Microsomal transfer protein inhibitors (MTPi) have the potential to be used as a drug to lower plasma lipids, mainly plasma triglycerides (TG). However, studies with animal models have indicated that ...",
        "The raising prevalence of type-2 diabetes mellitus and obesity has been recognized as a major problem for public health, affecting both developed and developing countries. Impaired fasting plasma gluc...",
        "The renin-angiotensin-aldosterone system (RAAS) is involved in the cardiovascular homeostasis as shown by previous studies reporting a positive association between specific RAAS genotypes and an incre...",
        "First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting\n\nFinerenone, a selective n..."
      ],
      "ground_truth": "SGLT2 inhibitors provide cardiovascular benefits by reducing major adverse cardiovascular events and hospitalization for heart failure, effects that appear to be independent of their glucose-lowering action.",
      "pipeline_name": "BasicRAG",
      "execution_time": 4.22800087928772,
      "num_docs": 5
    },
    {
      "query": "How do statins prevent cardiovascular disease?",
      "answer": "The context provided does not contain information specifically related to how statins prevent cardiovascular disease. The context primarily discusses the renin-angiotensin-aldosterone system (RAAS) and its genetic polymorphisms, the effects of Candesartan on insulin sensitivity, and the use of a microsomal triglyceride transfer protein (MTP) inhibitor to lower plasma triglycerides and LDL cholesterol concentrations in guinea pigs. Therefore, the information needed to answer how statins prevent cardiovascular disease is not available in the context provided.",
      "contexts": [
        "The renin-angiotensin-aldosterone system (RAAS) is involved in the cardiovascular homeostasis as shown by previous studies reporting a positive association between specific RAAS genotypes and an incre...",
        "The raising prevalence of type-2 diabetes mellitus and obesity has been recognized as a major problem for public health, affecting both developed and developing countries. Impaired fasting plasma gluc...",
        "Microsomal transfer protein inhibitors (MTPi) have the potential to be used as a drug to lower plasma lipids, mainly plasma triglycerides (TG). However, studies with animal models have indicated that ...",
        "Genetic insights into the effect of trace elements on cardiovascular diseases: multi-omics Mendelian randomization combined with linkage disequilibrium score regression analysis\n\nEpidemiological evide...",
        "Exploring novel markers for coronary heart disease associated with systemic lupus erythematosus: A review\n\nSystemic lupus erythematosus (SLE) is an autoimmune condition that is characterized by the pr..."
      ],
      "ground_truth": "Statins prevent cardiovascular disease by inhibiting HMG-CoA reductase to lower LDL cholesterol, reducing atherosclerotic plaque formation, and through pleiotropic effects such as anti-inflammatory and plaque-stabilizing properties.",
      "pipeline_name": "BasicRAG",
      "execution_time": 2.74959397315979,
      "num_docs": 5
    },
    {
      "query": "What is the role of ACE inhibitors in heart failure?",
      "answer": "Based on the context provided, it is mentioned that the renin-angiotensin-aldosterone system (RAAS) is involved in cardiovascular homeostasis and that specific RAAS genotypes have been associated with an increased risk of myocardial infarction. However, the specific role of ACE inhibitors in heart failure is not explicitly mentioned in the context. It is important to note that ACE inhibitors are commonly used in the treatment of heart failure as they help to block the conversion of angiotensin I to angiotensin II, which is a potent vasoconstrictor. This can help to reduce blood pressure, decrease the workload on the heart, and improve overall cardiac function in patients with heart failure.\n\nIn summary, while the context does not directly address the role of ACE inhibitors in heart failure, it is known that ACE inhibitors are commonly used in the treatment of heart failure to improve outcomes and reduce symptoms.",
      "contexts": [
        "The renin-angiotensin-aldosterone system (RAAS) is involved in the cardiovascular homeostasis as shown by previous studies reporting a positive association between specific RAAS genotypes and an incre...",
        "Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling\n\nCardiac fibrosis occurs in a wide range of cardiac diseases and is characterised by the transdifferent...",
        "Most case series suggest that less than half of the patients receiving a mechanical cardiac assist device as a bridge to recovery due to severe post-cardiotomy heart failure survive to hospital discha...",
        "Cardiomyocyte specific CD38 deletion protects heart from acute myocardial infarction by activating Sirt3 signaling pathway\n\nAcute myocardial infarction (AMI) is serious disease with high morbidity and...",
        "The heart is rich in cardiolipin, a phospholipid acylated in four sites, predominately with linoleic acid. Whether or not aging alters the composition of cardiolipin acyl chains is controversial. We t..."
      ],
      "ground_truth": "ACE inhibitors treat heart failure by blocking the conversion of angiotensin I to angiotensin II, which reduces vasoconstriction and aldosterone production, decreases afterload and preload, improves cardiac output, and ultimately reduces mortality and hospitalizations in patients with heart failure with reduced ejection fraction.",
      "pipeline_name": "BasicRAG",
      "execution_time": 3.4209768772125244,
      "num_docs": 5
    },
    {
      "query": "How do glucocorticoids suppress inflammation?",
      "answer": "Glucocorticoids, such as corticosteroids, are known to suppress inflammation by inhibiting the production of inflammatory cytokines and mediators. In the context provided, Document 1 discusses the use of corticosteroids as an anti-inflammatory therapy for cystic fibrosis (CF) patients. It mentions that corticosteroids have been proven to slow down the impairment of pulmonary function in CF patients, highlighting their anti-inflammatory effects. However, the use of corticosteroids is limited by the frequency of adverse events.\n\nDocument 2 provides additional information on the transport of cortisol, a glucocorticoid hormone, by the multidrug resistance gene product P-glycoprotein (Pgp). It shows evidence that cell lines with high expression of Pgp display reduced accumulation of cortisol and ATP-dependent outward transport of the hormone. This suggests that Pgp may play a role in regulating the levels of cortisol in cells.\n\nWhile the provided information supports the idea that glucocorticoids, such as cortisol, have anti-inflammatory effects, the exact mechanism by which glucocorticoids suppress inflammation is not explicitly discussed in the context. Additional information on how glucocorticoids interact with inflammatory pathways, such as inhibiting transcription factors like NF-\u03baB, suppressing the production of inflammatory cytokines, and promoting the resolution of inflammation, would be needed to provide a more comprehensive answer.",
      "contexts": [
        "Chronic neutrophil inflammation of the respiratory tract tissues plays a key role in the pathogenesis and in prognosis of cystic fibrosis (CF). It is evident that an anti-inflammatory therapy represen...",
        "The physiology of the multidrug transporter P-glycoprotein (Pgp) is still poorly understood. We now show evidence that cell lines with a high expression of Pgp display a reduced accumulation of cortis...",
        "Anti-inflammatory and barrier repair mechanisms of active components in \n\nDaemonorops draco D. draco D. draco D. draco The online version contains supplementary material available at 10.1038/s41598-02...",
        "Menisoxoisoaporphine A, a novel oxoisoaporphine alkaloid from Menispermi Rhizoma, inhibits inflammation by targeting PDE4B\n\nDysregulated and excessive inflammatory reactions can lead to tissue damage,...",
        "Modulation of the central nervous system immune response and neuroinflammation via Wnt signaling in health and neurodegenerative diseases\n\nThe immune response in the central nervous system (CNS) is a ..."
      ],
      "ground_truth": "Glucocorticoids suppress inflammation by binding to cytoplasmic glucocorticoid receptors that translocate to the nucleus, where they suppress pro-inflammatory gene transcription and induce anti-inflammatory protein expression.",
      "pipeline_name": "BasicRAG",
      "execution_time": 4.138968229293823,
      "num_docs": 5
    },
    {
      "query": "What are the mechanisms of antibiotic resistance?",
      "answer": "Based on the information provided in the context, the mechanisms of antibiotic resistance include the genetic location of resistance determinants in MRSA isolates studied in Kuwait hospitals between 1994-2004. The resistance determinants were determined through curing and transfer experiments. Additionally, the presence of antibiotic resistance genes (ARGs) in indoor dust samples from workplaces and households was explored in a pilot study, highlighting the importance of understanding the resistome in different environments. The context also mentions the emerging carbapenem-resistant Klebsiella pneumoniae as a contributor to antimicrobial resistance.\n\nHowever, the context does not provide a detailed breakdown of specific mechanisms of antibiotic resistance such as efflux pumps, target modification, or enzymatic inactivation. Further information on the specific genetic mechanisms and pathways involved in antibiotic resistance in MRSA isolates, hypermucoviscous and non-hypermucoviscous bacteria, and indoor dust samples would be needed to provide a comprehensive answer to the question.",
      "contexts": [
        "Methicillin-resistant  Staphylococcus aureus  Between April 1994 and December 2004, 5644 MRSA isolates obtained from different clinical samples were studied for resistance to antibacterial agents acco...",
        "Antimicrobial resistance in hypermucoviscous and non-hypermucoviscous \n\nAntimicrobial resistance has recently increased due to emerging carbapenem-resistant  Klebsiella pneumoniae K. pneumoniae K. pne...",
        "Resistome in the indoor dust samples from workplaces and households: a pilot study\n\nThe antibiotic resistance genes (ARGs) limit the susceptibility of bacteria to antimicrobials, representing a proble...",
        "To unravel molecular targets involved in glycopeptide resistance, three isogenic strains of  Staphylococcus aureus  S. aureus  In the absence of antibiotic selection pressure, comparison of stable res...",
        "Daptomycin is a novel cyclic lipopeptide whose bactericidal activity is not affected by current antibiotic resistance mechanisms displayed by  S. aureus  S. aureus  The methicillin-susceptible  S. aur..."
      ],
      "ground_truth": "Bacteria develop antibiotic resistance through target gene mutations, horizontal gene transfer of resistance genes via plasmids or transposons, and expression of efflux pumps that remove antibiotics from the cell.",
      "pipeline_name": "BasicRAG",
      "execution_time": 3.8967080116271973,
      "num_docs": 5
    },
    {
      "query": "How do biologics treat rheumatoid arthritis?",
      "answer": "Biologics treat rheumatoid arthritis by targeting specific molecules in the immune system that play a role in the inflammation and joint damage seen in the disease. In Document 3, the study focuses on the effects of biologic or target synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) on knee symptoms in patients with rheumatoid arthritis. Biologics such as IL-6, JAK, TNF inhibitors, and CTLA4-Ig are mentioned as potential treatments for rheumatoid arthritis in this context.\n\nIL-6 inhibitors, JAK inhibitors, TNF inhibitors, and CTLA4-Ig are all types of biologic drugs that target different pathways involved in the inflammatory response seen in rheumatoid arthritis. These drugs work by blocking specific proteins or receptors involved in the immune response, thereby reducing inflammation and slowing down the progression of joint damage in patients with rheumatoid arthritis.\n\nIn Document 2, the natural compound Usenamine A is mentioned as a potential therapeutic agent for rheumatoid arthritis and ankylosing spondylitis through its anti-inflammatory activity. This compound could potentially act as a biologic drug to target inflammation in these diseases.\n\nOverall, biologics work by targeting specific molecules in the immune system to reduce inflammation and alleviate symptoms in patients with rheumatoid arthritis.",
      "contexts": [
        "Analysis of biomarkers in synovial tissue is increasingly used in the evaluation of new targeted therapies for patients with rheumatoid arthritis (RA). This study determined the intrarater and inter-r...",
        "Usenamine A: a potential therapeutic agent for rheumatoid arthritis and ankylosing spondylitis through its anti-inflammatory activity\n\nUsenamine A (UA) is a natural compound isolated from the lichen  ...",
        "Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis\n\nThis study aims to identify factors influencing the alleviation of knee joint symptoms in pat...",
        "Rho is a major small GTP-binding protein that is involved in the regulation of various cell functions, including proliferation and cell migration, through activation of multiple signaling molecules in...",
        "Quantitative traits such as complex diseases are controlled by many small-effect genes that are difficult to identify. Here we present a novel strategy to identify the candidate genes for small-effect..."
      ],
      "ground_truth": "Biologics treat rheumatoid arthritis by targeting specific components of the immune system, such as blocking TNF or IL-6 signaling, or depleting B cells to reduce autoantibody production, thereby interrupting the inflammatory cascade that causes joint damage.",
      "pipeline_name": "BasicRAG",
      "execution_time": 3.7964189052581787,
      "num_docs": 5
    },
    {
      "query": "What is the mechanism of action of levodopa in Parkinson's disease?",
      "answer": "The context provided does not contain information regarding the mechanism of action of levodopa in Parkinson's disease. The context primarily discusses the need for new disease-modifying treatments for Parkinson's disease and mentions studies on metformin and GDNF-transfected macrophages as potential adjunctive therapies. Levodopa is a commonly used medication in the treatment of Parkinson's disease as it helps to replenish dopamine levels in the brain. The mechanism of action of levodopa involves its conversion into dopamine in the brain, which can then help alleviate the motor symptoms of Parkinson's disease.",
      "contexts": [
        "Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson\u2019s disease\n\nParkinson\u2019s disease (PD) is caused by the progressive loss of dopaminergic neuron...",
        "Retraction: GDNF-Transfected Macrophages Produce Potent Neuroprotective Effects in Parkinson\u2019s Disease Mouse Model\n\n",
        "",
        "The interplay between epitranscriptomic RNA modifications and neurodegenerative disorders: Mechanistic insights and potential therapeutic strategies\n\nNeurodegenerative disorders encompass a group of a...",
        "Serum glial fibrillary protein reflects early brain injury dynamics and cognitive changes after deep brain stimulation surgery\n\nDeep brain stimulation (DBS) is an efficient treatment for movement diso..."
      ],
      "ground_truth": "Levodopa treats Parkinson's disease by crossing the blood-brain barrier and being converted to dopamine in the brain, helping to replenish depleted dopamine levels in the striatum and compensate for the loss of dopaminergic neurons in the substantia nigra.",
      "pipeline_name": "BasicRAG",
      "execution_time": 2.7798640727996826,
      "num_docs": 5
    }
  ],
  "average_ragas_scores": {}
}